|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> >> 市场分析报告 |
市场分析报告 |
|
Intrahepatic Cholangiocarcinoma - Pipeline Insight, 2021 ... . Intrahepatic Cholangiocarcinoma Emerging Drugs Derazantinib: Basilea Pharmaceutica Derazantinib is an orally administered small molecule ... factor receptor (FGFR) family of kinases. Derazantinib is currently in a registrational phase 2 study inIntrahepatic ... Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity & Clinical Trials Insight 2026 Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location. “Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity & Clinical Trials Insight 2026” Report Highlights: Global FGFR ... Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2018 Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2018 SUMMARY According to the recently published report 'Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2018'; Fibroblast ... Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H2 2018 Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H2 2018 SUMMARY Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It ... Fibroblast Growth Factor Receptor 4 - Pipeline Review, H1 2020 Fibroblast Growth Factor Receptor 4 - Pipeline Review, H1 2020 SUMMARY Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) pipeline Target constitutes close to 23 molecules. Out of which approximately 21 molecules are developed by companies ... Macrophage colony stimulating factor receptor antagonists - Pipeline Insight, 2022 ... PLX4720 Edicotinib ABSK 021 Chiauranib Derazantinib NMS 03592088 Q 702 Emactuzumab Elzovantinib ... Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) ... Adrenocortical Carcinoma (Adrenal Cortex Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Adrenocortical Carcinoma (Adrenal Cortex Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenocortical ... ArQule Inc (ARQL) - Financial and Strategic SWOT Analysis Review ... molecule, also an inhibitor of AKT and Derazantinib (ARQ 087), a multi kinase inhibitor ... |